Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Unity Biotechnology, Inc. (UBX)

3.39   -0.15 (-4.24%) 06-09 14:39
Open: 3.59 Pre. Close: 3.54
High: 3.609 Low: 3.27
Volume: 112,840 Market Cap: 49(M)

Technical analysis

as of: 2023-06-09 2:18:11 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 4.42     One year: 5.17
Support: Support1: 2.85    Support2: 2.26
Resistance: Resistance1: 3.78    Resistance2: 4.42
Pivot: 3.14
Moving Average: MA(5): 3.42     MA(20): 3.05
MA(100): 3.33     MA(250): 4.13
MACD: MACD(12,26): 0.2     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 68.8     %D(3): 72.3
RSI: RSI(14): 60.5
52-week: High: 18.5  Low: 1.46
Average Vol(K): 3-Month: 447 (K)  10-Days: 256 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ UBX ] has closed below upper band by 24.4%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.74 - 3.76 3.76 - 3.77
Low: 3.32 - 3.34 3.34 - 3.35
Close: 3.51 - 3.54 3.54 - 3.56

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Headline News

Tue, 30 May 2023
Should You Buy Unity Biotechnology Inc (UBX) Stock After it Is Lower By 5.88% in a Week? - InvestorsObserver

Fri, 26 May 2023
Is Unity Biotechnology Inc (UBX) a Winner in the Biotechnology Industry? - InvestorsObserver

Tue, 09 May 2023
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates - Yahoo Finance

Mon, 24 Apr 2023
Unity Biotechnology Inc (UBX) is higher by 0.87% Monday In Premarket Trading - InvestorsObserver

Tue, 18 Apr 2023
Is Unity Biotechnology Inc (UBX) Stock About to Get Hot Tuesday? - InvestorsObserver

Mon, 10 Apr 2023
Unity Biotechnology Inc (UBX) has gained 0.61% in a Week, Should You Sell? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 14 (M)
% Held by Insiders 1.313e+007 (%)
% Held by Institutions 1.7 (%)
Shares Short 1,200 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.618e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -20
Return on Assets (ttm) 363.5
Return on Equity (ttm) -26.5
Qtrly Rev. Growth 236000
Gross Profit (p.s.) 0
Sales Per Share -135.59
EBITDA (p.s.) -5.03143e+007
Qtrly Earnings Growth -4.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -47 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0.58

Stock Dividends

Dividend 0
Forward Dividend 952220
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.